Volume 15, Number 5—May 2009
Dispatch
Reduced Fluoroquinolone Susceptibility in Salmonella enterica Isolates from Travelers, Finland
Table
Country visited | No. (%) isolates | No. isolates with CIP MIC >0.125 µg/mL | No. isolates with NAL MIC >32 µg/mL | No. isolates with NAL MIC <32 µg/mL | No. trips from Finland during study months† |
---|---|---|---|---|---|
Thailand‡ | 212 (42.5) | 98 | 67 | 31 | 122,472 |
Spain§ | 66 (13.2) | 25 | 25 | 0 | 426,822 |
Brazil | 41 (8.2) | 0 | 0 | 0 | 25,009 |
Egypt | 40 (8.0) | 17 | 17 | 0 | 47,291 |
India | 32 (6.4) | 7 | 7 | 0 | 26,233 |
Malaysia | 15 (3.0) | 6 | 1 | 5 | 2,597 |
Vietnam | 9 (1.8) | 2 | 2 | 0 | 7,555 |
Tanzania | 9 (1.8) | 2 | 2 | 0 | 1,259 |
Portugal | 8 (1.6) | 7 | 7 | 0 | 35,899 |
Morocco | 5 (1.0) | 3 | 3 | 0 | 8,708 |
Other areas |
62 (12.4) |
14 |
14 |
0 |
|
Total | 499 (100) | 181 | 145 | 36 |
*CIP, ciprofloxacin; NAL, nalidixic acid.
†Data collected from statistics reports, Finland, based on the no. of Finnish travelers to these countries.
‡No. Finnish travelers to Thailand from 2003 to 2007: 21,873; 22,882; 17,661; 21,941; and 38,115, respectively.
§Includes Canary Islands.
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.